Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 special interest group)

Journal of Rheumatology

Volumn 36, Issue 10, 2009, Pages 2335-2341

  Bingham III, Clifton O ^a   Pohl, Christoph ^b   Woodworth, Thasia G ^c   Hewlett, Sarah E ^e   May, James E ^f   Rahman, Mahboob U ^g   Witter, James P ^h   Furst, Daniel E ^d   Strand, C Vibeke ⁱ   Boers, Maarten ^j   Alten, Rieke E ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Schlosspark Klinik   (Germany)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^f University of Pennsylvania ^*

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j VU UNIVERSITY AMSTERDAM   (Netherlands)

more..

Author keywords

Disease activity; Flare; Outcome measures; Patient perspective; Rheumatoid arthritis; Worsening

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ABSORPTIOMETRY; CONFERENCE PAPER; CONSENSUS; DELPHI STUDY; DISEASE ACTIVITY; DISEASE DURATION; EVIDENCE BASED PRACTICE; GRIP STRENGTH; HUMAN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SELF REPORT; SENSITIVITY ANALYSIS; STANDARDIZATION; SYNOVITIS;

EID: 70450179790     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090369     Document Type: Conference Paper

References (37)

1. Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007;34:1401-1414 (Pubitemid 46898128)
2. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-1064 (Pubitemid 34493514)
3. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-769
4. Giles JT, Mease P, Boers M, et al. Assessing single joints in arthritis clinical trials. J Rheumatol 2007;34:641-647 (Pubitemid 46364024)
5. Wells G, Boers M, Shea B, et al. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. J Rheumatol 2003;30:1110-1111 (Pubitemid 36529643)
6. Wells G, Anderson J, Boers M, et al. MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. J Rheumatol 2003;30:1115-1118 (Pubitemid 36529645)
7. Leeb BF, Sautner J, Leeb BA, Fassl C, Rintelen B. Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes. Scand J Rheumatol 2006;35:441-446 (Pubitemid 47215711)
8. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987;82:781-786
9. Yazici Y, Erkan D, Kulman I, Belostocki K, Harrison MJ. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world". Ann Rheum Dis 2002;61:638-640
10. Fleischmann RM, Cohen SB, Moreland LW, et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin 2005;21:1181-1190
11. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-1238 (Pubitemid 47309743)
12. Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 2000;43:1010-1015 (Pubitemid 30368177)
13. Ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-352 (Pubitemid 26046101)
14. Van den Bemt BJ, den Broeder AA, Snijders GF, et al. Sustained effect after lowering high dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008;67:1697-1701
15. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007;56:2129-2134 (Pubitemid 47173559)
16. Maravic M, Berge C, Daures JP, Boissier MC. Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. Clin Exp Rheumatol 2005;23:36-42. (Pubitemid 40424756)
17. Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880-883
18. Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G. Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. Arthritis Rheum 2001;44:53-60. (Pubitemid 32113118)
19. Den Broeder AA, Creemers MC, van Gestel AM, van Riel PL. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology 2002;41:638-642 (Pubitemid 34618881)
20. de Man YA, Hazes JM, van de Geijn FE, Krommenhoek C, Dolhain RJ. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:716-722 (Pubitemid 46932075)
21. Caldwell JR, Furst DE, Smith AL, et al. Flare during drug withdrawal as a method to support efficacy in rheumatoid arthritis: amiprilose hydrochloride as an example in a double blind, randomised study. J Rheumatol 1998;25:30-35
22. Aletaha D, Stamm T, Smolen J. [Measuring disease activity for rheumatoid arthritis]. Z Rheumatol 2006;65:93-6, 98-102.
23. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209 (Pubitemid 27430130)
24. Ruperto N, Lovell DJ, Goodman S, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Data over two years of treatment in a phase III Study [abstract]. Ann Rheum Dis 2007;66 Suppl II:THU0195.
25. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:348-350
26. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372-1379 (Pubitemid 37407029)
27. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-691 (Pubitemid 29520536)
28. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-2558 (Pubitemid 41785892)
29. Furst D, Chang H, Ranganath V, et al. Defining change in disease activity parameters associated with loss of response over time in RA patients [abstract]. Arthritis Rheum 2007;56 Suppl:S709.
30. Kirwan J, Heiberg T, Hewlett S, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003;30:868-872 (Pubitemid 36402790)
31. Kirwan JR, Ahlmen M, de Wit M, et al. Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. J Rheumatol 2005;32:2246-2249 (Pubitemid 41587876)
32. Kirwan JR, Hewlett S. Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 2007;34:1171-1173 (Pubitemid 46774869)
33. Kirwan JR, Minnock P, Adebajo A, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-1177 (Pubitemid 46774870)
34. Strand V, Crawford B. Improvement in health-related quality of life in patients with systemic lupus erythematosus following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoeconomics Outcomes Res 2005;5:317-326 (Pubitemid 40894969)
35. Stucki G, Cieza A, Geyh S, et al. ICF core sets for rheumatoid arthritis. J Rehabil Med 2004;44 Suppl:87-93. (Pubitemid 39307116)
36. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;44:143-150 Epub 2006 Oct 26 (Pubitemid 46226045)
37. Gotzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 1996;25:194-199 (Pubitemid 26273849)